艾迪联合GP方案治疗晚期非小细胞肺癌的临床观察

目的　观察艾迪注射液联合吉西他滨及顺铂化疗（GP方案）治疗晚期非小细胞肺癌的近期疗效和毒副反应。方法　63例经病理学或细胞学证实的晚期非小细胞肺癌患者分为对照组(GP方案)和治疗组(艾迪联合GP方案)。对照组应用吉西他滨1 000 mg/m2,静滴,d1, 8;顺铂80 mg/m2,分割为第1~3天,静滴;治疗组在此基础上加用艾迪注射液80 ml静滴, d1-14; 21 d为1周期,完成2周期后进行疗效评价。结果　两组近期疗效差异无统计学意义(P>0·05)；临床受益反应(CBR)在KPS评分及体重增加、止痛药用量减少三项指标上治疗组均明显优于对照组(P<0·05)。结论　艾迪注射液联合化疗具有改善生活质量和明显协同、增效、减毒作用,且毒副反应轻微,可作为化疗的重要辅助用药。

Aidi injection combined with chemotherapy for treatment of the advanced non-small cell lung cancer

Objective To observe the efficacy and toxicity of Aidi injection combined with chemotherapy in treatment of advanced non-small cell lung cancer and the life quality of the patients. Methods 63 cases of advanced NSCLC were divided into two groups: The patients for GP: gemcitabine 1 000 mg/m2, d1, 8 plus cisplatin 80 mg/m2, division d1-3; Aidi and GP: add Aidi 80 ml/d, d1-14; interval between each cycle was 21 days and the clinical response and the toxicity were assessed after2 cycles·Results Overall response rates(CR+PR) were similar (P>0·05); CBR: Aidi and GP was obviously different for GP(P<0·05) in three ways: KPS>20, weight augment>7%, anodyne reduce 50·0%。Conclusion Aidi plus gemcitabine and cisplatin is an effective and mild toxicity combined with chemotherapy for advanced non-small cell lung cancer·.